Evaluation of the Risk of Psoriatic Arthritis in Patients With Psoriasis Undergoing Biological Treatment. Global Population Study (TRINETX)
This study highlights differential PsA risk among PsO patients on biologic therapy, suggesting potential benefits of IL12/23i and IL23i in PsA prevention. Prospective studies are needed to confirm these findings and optimize PsA prevention strategies.
Authors
- Gema Hernández (ORCID: https://orcid.org/0000-0003-4832-455X)
- Beatriz Joven (ORCID: https://orcid.org/0000-0003-1140-7618)
- José L. Pablos (ORCID: https://orcid.org/0000-0001-7229-6005)
- Pablo L. Ortiz‐Romero (ORCID: https://orcid.org/0000-0003-2985-9639)
- Raquel Rivera (ORCID: https://orcid.org/0000-0002-4604-0724)
- Carmen García‐Donoso
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital Universitario 12 De Octubre (ES)
- TriNetX (United States) (US)
Publication Details
- Journal
- Actas Dermo-Sifiliográficas
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1016/j.ad.2025.104488
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00